GSK321
CAS No. 1816331-63-1
GSK321( —— )
Catalog No. M34615 CAS No. 1816331-63-1
GSK321 is a selective and potent mutant isocitrate dehydrogenase 1 (IDH1) inhibitor that inhibits lipid synthesis and blocks cell proliferation in OPA1-deficient MEFs and prevents cytoplasmic glutamine reductive carboxylation.GSK321 has been used in the study of leukemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK321
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK321 is a selective and potent mutant isocitrate dehydrogenase 1 (IDH1) inhibitor that inhibits lipid synthesis and blocks cell proliferation in OPA1-deficient MEFs and prevents cytoplasmic glutamine reductive carboxylation.GSK321 has been used in the study of leukemia.
-
DescriptionGSK321 is a potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) enzymes. GSK321 has high inhibitory and selectivity for mutant IDH1 enzymes. GSK321 can be used for the research of acute myeloid leukemia.
-
In VitroGSK321 has high inhibitory for mutant IDH1 enzymes, with IC50 values of 4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G, respectively.GSK321 (0, 0.5, 5 μM; 48 h) induces markedly decreased H3K9me2 levels.GSK321 decreases intracellular 2-HG and affects proliferation of primary IDH1 mutant AML cells.GSK321 has inhibition activity for mutant IDH1 that overcomes the pathognomonic differentiation block of AML cells, and induces myeloid differentiation of IDH1 mutant cells at the level of leukemic blasts and more stem-like cells.GSK321 leads to genome-wide DNA cytosine hypomethylation in IDH1-mutant AML cells.Western Blot Analysis Cell Line:HT-1080 cells Concentration:0, 0.5, 5 μM Incubation Time:48 h Result:Lead to the reduction of histone H3K9 dimethylation (H3K9me2).Cell Proliferation Assay Cell Line:IDH1 mutant AML cells Concentration:3 μM Incubation Time:15 days Result:Showed a significant, initial increase in cell numbers (2-fold to 15-fold) in IDH1 mutant AML cells.Cell Cycle Analysis Cell Line:IDH1 mutant AML cells Concentration: Incubation Time:7 days Result:Observed a reproducible and significant decrease in quiescent (G0)-phase cells in R132G IDH1 and R132C IDH1 AML cells.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorDehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1816331-63-1
-
Formula Weight501.55
-
Molecular FormulaC28H28FN5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (498.45 mM; Ultrasonic )
-
SMILESC(N1C2=C(C(C(NC3=CC([C@H](C)O)=CC=C3)=O)=N1)CN(C(=O)C4=CC=CN4)C[C@H]2C)C5=CC=C(F)C=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ujunwa C Okoye-Okafor, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol. 2015 Nov;11(11):878-86.?
molnova catalog
related products
-
CM 10
CM 10 is an aldehyde dehydrogenase 1A family(ALDH1A) inhibitor.
-
hDHODH-IN-5
hDHODH-IN-5 is an inhibitor of human dihydroorotate dehydrogenase.
-
Epostane
Epostane acts as an antiprogestogen and terminates pregnancy by inhibiting 3β-hydroxysteroid dehydrogenase and preventing the biosynthesis of progesterone and pregnenolone.
Cart
sales@molnova.com